TransCode Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 18.55 million compared to USD 17.56 million a year ago. Basic loss per share from continuing operations was USD 103.61 compared to USD 1,082.79 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | +30.39% | +88.12% | -79.82% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-79.82% | 6.23M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- RNAZ Stock
- News TransCode Therapeutics, Inc.
- TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023